Remygen - Diamyd

Drug Profile

Remygen - Diamyd

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Diamyd Medical AB
  • Class Antihyperglycaemics
  • Mechanism of Action GABA agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 24 Oct 2017 Diamyd Medical enters into a licensing agreement with University of California for remygen
  • 27 Sep 2017 Diamyd files for patent protection for Remygen
  • 27 Sep 2017 Preclinical trials in Diabetes mellitus in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top